Cite
Becker M, Graf C, Tonak M, et al. Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. Oncol Lett. 2016;12(2):1257-1264doi: 10.3892/ol.2016.4784.
Becker, M., Graf, C., Tonak, M., Radsak, M. P., Bopp, T., Bals, R., Bohle, R. M., Theobald, M., Rommens, P. M., Proschek, D., & Wehler, T. C. (2016). Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. Oncology letters, 12(2), 1257-1264. https://doi.org/10.3892/ol.2016.4784
Becker, Marc, et al. "Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents." Oncology letters vol. 12,2 (2016): 1257-1264. doi: https://doi.org/10.3892/ol.2016.4784
Becker M, Graf C, Tonak M, Radsak MP, Bopp T, Bals R, Bohle RM, Theobald M, Rommens PM, Proschek D, Wehler TC. Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. Oncol Lett. 2016 Aug;12(2):1257-1264. doi: 10.3892/ol.2016.4784. Epub 2016 Jun 24. PMID: 27446424; PMCID: PMC4950181.
Copy
Download .nbib